Drug notes:
PT886 Clin1 multiple cancers (ODD); PTC-217 Clin1 cancers; 15 add'l products early stage
About:
Phanes Therapeutics is focused on innovative drug discovery in immuno-oncology. Antibiotic-based biologics have much potential in therapies due to their specificity and modularity. Phanes is building native IgG-like bispecific antibodies that enhance drug-like properties. Currently, Phane has three technology platforms: PACbody, to create bispecific antibodies, SPECpair, to enhance manufacturability of bispecific antibodies and ATACCbody, to build bispecific antibodies with modulated activities. Using this approach, Phanes has established a diverse pipeline with some programs in clinical studies.